Across TCGA pan-cancer cohorts, KCNH7 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KCNH7 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher KCNH7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KCNH7 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

READ, PRAD, and ACC are the cancer types where KCNH7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	II,III,IV	0.166	0.829	<.001	11	view →
PRAD	DFS	Median	All	0.664	0.936	.005	6	view →
ACC	OS	Median	All	0.161	0.632	.022	6	view →
ESCA	OS	Median	II,III,IV	0.277	0.686	.026	6	view →
UCEC	DFS	Median	II,III,IV	0.802	0.433	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: KCNH7 tumor-vs-normal RNA expression · all KCNH7 data types